Good morning, myeloma world.

Things have settled down here at Myeloma Morning Headquarters compared to how they were 36 hours ago. We once again have 21^st century tech­nology doing what it is supposed to be doing. It's wonderful.

Speaking of wonderful, let's talk some more about the multiple myeloma research to be presented at the upcoming 2016 annual meeting of the American Society of Clinical Oncology (ASCO). We discussed the meeting in the previous edition of Myeloma Morning, noting …

We hope you had a pleasant Wednesday, myeloma world.

Our Wednesday was going full steam ahead until modern tech­nology at Myeloma Morning Headquarters decided to take a vaca­tion. And this had to hap­pen, of course, on a day when we have some particularly in­ter­est­ing devel­op­ments to discuss.

What “developments” might those be, you ask?

Well, those “developments” would be the titles of all pre­sen­ta­tions to be given at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). …

A happy Tuesday to you, myeloma world.

We have some in­ter­est­ing re­search to share with you.

First, we have re­­sults of a Phase 2 study investi­gating Empliciti (elotuzu­mab) in com­bi­na­tion with Velcade (bor­tez­o­mib) and dexa­metha­sone (Decadron) in re­lapsed and re­frac­tory myeloma patients. The re­­sults show that Empliciti plus Velcade and dexa­metha­sone im­proves pro­gres­sion-free sur­vival com­pared to Velcade and dexa­metha­sone alone, without adding any sig­nif­i­cant side effects.

We also report on a study out of Italy that explores using

Good day, myeloma world.

Monday's tend to be quiet here at Myeloma Morning Headquarters – at least when it comes to new research that needs to be reviewed and summarized. Today is no exception. There was no new myeloma-related research when we checked this morning, and just one or two news items.

We do have a few things, however, that we'd like to review with you.

First, we mentioned last week that this month's issue of the Journal of …

A wonderful Sunday to you, myeloma world.

We hope that, wherever you may be today, the sun is shining as brightly as it is here at Myeloma Morning Headquarters, and that the sky is as blue.

In today's Myeloma Morning, we'll be summarizing two new myeloma-related research studies. We also have “Quickly Noted” descriptions of two additional studies. Overall, there are five items in our daily list of new multiple myeloma research, which – as always – …

A pleasant weekend to you, myeloma world.

Today is a quiet day in terms of new myeloma-related research and news. We've got just two items in our daily list of new myeloma research, which you can always find at the end of every Myeloma Morning. The article's in today's list are specialized enough that we won't be summarizing them in this report.

We do want to mention, however, that the 2016 annual meeting of the American Association …

Hello again, myeloma world.

As we continue catching up after the recent onslaught of new myeloma-related research, we're pleased to report that it's a sunny spring day outside. More importantly, our top story today reflects Mother Nature's pleasant disposition.

In particular, there is updated data about multiple myeloma survival in the United States, and it's good news.

It's just an annual update – a single new value for survival five-years from the time of diagnosis. And it's for patients diagnosed …